Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $2.41
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 19, 26 |
Daily · Wilder smoothing
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| Sep 14, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 6, 26 | Guggenheim | maintain | Buy | Buy |
| Aug 15, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 3, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jan 27, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 18, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 22, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jun 28, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 39.41 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 37.61 | Oscillator | Neutral |
| Williams %R (14) | -63.30 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.24 (Hist 0.01) | Oscillator | Buy |
| Average Directional Index (14) | 19.95 (+DI 15.8 / -DI 25.4) | Trend | Neutral |
| EMA 20 | 2.64 | MA | Strong Sell |
| SMA 20 | 2.67 | MA | Strong Sell |
| EMA 50 | 3.02 | MA | Strong Sell |
| SMA 50 | 3.19 | MA | Strong Sell |
| SMA 200 | 3.40 | MA | Strong Sell |
Stock news · updated daily
Adagene (NASDAQ: ADAG - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Monday, MarketBeat.com reports. They presently have a $7.00 target price on the stock. HC Wainwright's price target would suggest a potential upside of 219.63% from the company's previous close. A
Adagene (NASDAQ: ADAG) Chairman, CEO and Co-Founder Peter Luo outlined the clinical-stage biotechnology company's antibody pipeline, its approach to masked therapies and upcoming development milestones during a discussion focused on its T-cell engager, or TCE, portfolio. Luo said Adagene's development strategy centers on targeting tumors while limiting effects on healthy tissue through its SAFEbody platform. The
Adagene NASDAQ: ADAG Chairman, CEO and Co-Founder Peter Luo outlined the clinical-stage biotechnology company's antibody pipeline, its approach to masked therapies and upcoming development milestones during a discussion focused on its T-cell engager, or TCE, portfolio.
SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in a fireside chat at the H.C.
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene's proprietary SAFEbody® precision masking technology on both HER2 and CD3 binding sites to enable tumor-selective therapy with low systemic toxicity Preclinical data demonstrated robust tumor regression in tumor models refractory and/or resistant to Enhertu, along with strong synergy in combination with anti-CTLA-4, anti-PD-1 or anti-CD137 antibodies SAN DIEGO and SUZHOU, China, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that China's National Medical Products Administration (NMPA) has approved the company's investigational new drug (IND) application for ADG138, a double-masked HER2×CD3 bispecific T cell engager built on Adagene's proprietary SAFEbody® precision masking technology.
Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) CEO Peter Luo acquired 20,290 shares of the business's stock in a transaction dated Wednesday, September 16th. The shares were acquired at an average price of $3.15 per share, for a total transaction of $63,913.50. Following the acquisition, the chief executive officer directly owned 88,535 shares
Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -0.22 | -0.23 | Miss -4.5% | $1.61M |
| Apr 1, 2026 | -0.28 | -0.07 | Beat 75.0% | $7.69M |
| Mar 23, 2026 | -0.19 | -0.11 | Beat 42.4% | $7.69M |
| Aug 12, 2025 | -0.32 | -0.23 | Beat 28.1% | — |
| Mar 24, 2025 | -0.33 | -0.29 | Beat 12.1% | $103.0K |
| Jul 25, 2024 | -0.41 | -0.31 | Beat 24.4% | — |
| 4 | Sep 17, 2026 | 2026-09-17 06:11:33 | View |
| 6-K | Sep 10, 2026 | 2026-09-10 08:00:11 | View |
| 6-K | Sep 9, 2026 | 2026-09-09 08:00:08 | View |
| 4 | Aug 18, 2026 | 2026-08-18 18:11:19 | View |
| 4 | Aug 17, 2026 | 2026-08-17 20:32:25 | View |
| 4 | Aug 17, 2026 | 2026-08-17 20:30:36 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | ADAG | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -5.1x | -2.8x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -5.0x | EPS est. -0.48 | In line |
| Price / Book | 1.0x | 1.3x | Discount |
| Price / Sales | 9.7x | 147.6x | Discount |
| EV / EBITDA | 1.4x | 0.1x | Elevated |
| Return on equity | -29.1% | — | Weak |
| Gross margin | 94.2% | -79.5% | Below hist. |
| Debt / Equity | 0.06 | 0.25 | Conservative |
| Piotroski / Altman Z | 4/9 | Z -1.17 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 30, 26 | Gu Chunfang | officer | 0 | — | |
| Sep 23, 26 | Tam Man Kin | director, officer: Chief Financial Officer | P-Purchase | 2,000 @ $3.00 | $6.00K |
| Sep 16, 26 | Luo Peter | director, officer: Chief Executive Officer | P-Purchase | 20,290 @ $3.15 | $63.98K |
| Aug 14, 26 | Do Cuong V | director | P-Purchase | 2,000 @ $3.75 | $7.50K |
| Aug 13, 26 | Zhu Li | director | A-Award | 20,000 @ $3.00 | $60.00K |
| Aug 13, 26 | Cheung Andy Yiu Leung | director | A-Award | 20,000 @ $3.00 | $60.00K |
| Aug 13, 26 | Do Cuong V | director | A-Award | 20,000 @ $3.00 | $60.00K |
| Aug 13, 26 | Grawunder Ulf | director | A-Award | 20,000 @ $3.00 | $60.00K |
FY2020 · 10-K disclosure